期刊文献+

放射引导的多肽特异性传输在肝癌放化疗模型中的应用 被引量:1

Application of radiation-guided peptide delivery on radiotherapy and chemotherapy model of hepatic carcinoma
在线阅读 下载PDF
导出
摘要 目的本课题拟通过重组HVGGSSV多肽,研究其特异性结合放射损伤肿瘤细胞的特性,并观察其体内分布及代谢情况,为肝癌特异性靶向治疗提供新方法。方法采用荧光染料Cy7-NHS ester标记HVGGSSV,合成Cy7-HVGGSSV。建立人肝癌裸鼠双后肢种植瘤模型,所有小鼠首先经顺铂(DDP)处理,然后小鼠右后肢肿瘤放射处理3Gy,左后肢处肿瘤不接受放射处理,将其随机分为对照和实验组,每组5只小鼠,放射后4小时,实验组和对照组分别经尾静脉注射Cy7-HVGGSSV和Cy7-NHS ester。通过小动物活体成像系统检测并观察小鼠体内不同时间点的荧光分布情况。结果实验组右后肢肿瘤荧光强度在给药后1小时、2小时、15小时、24小时、48小时分别比左后肢肿瘤高(5.82±1.24)×10~7photons/(s·cm2)、(8.99±1.27)×10~7 photons/(s·cm^2)、(4.04±2.30)×10~7 photons/(s·cm2)、(6.52±3.93)×10~7 photons/(s·cm^2)、(9.33±1.74)×107 photons/(s·cm^2)。实验组较对照组右后肢肿瘤荧光强度分别提高(18.4±1.33)×107 photons/(s·cm^2)、(17.1±1.64)×107 photons/(s·cm^2)、(55.8±2.66)×107photons/(s·cm^2)、(68.9±3.97)×107 photons/(s·cm^2)、(16.3±1.67)×107 photons/(s·cm^2)。对照组荧光分布无特异性。48 h后,实验组小鼠的肝脏及肾脏具有较高荧光量分布。结论 HVGGSSV可以特异性结合放射损伤的肝癌移植瘤,其主要通过肝脏及肾脏代谢,有可能为放射引导的药物提供靶向运输载体。 Objective To investigate the characteristics of peptide HVGGSSV, which specifically binds to irradiated tumors, and its biological distribution in vivo in order to provide a new way for targeted cancer therapy of hepatic carcinoma. Methods HVGGSSV peptide was conjugated to Cy7-NHS ester for nearinfrared fluorescence imaging. The nude mice models of hepatic carcinoma which implanted in both hind limbs were established, and all of them were injected through intraperitoneal with DDP before treated with radiation. Only the tumor on the right side of each mouse received a radiation dose of 3 Gy, while the tumor on the left side received no radiation. All mice were divided into two groups with 5 mice each. Four hours later, experimental group and control group were injected with Cy7-HVGGSSV and Cy7-NHS ester, respectively. All mice were anesthetized and quantified with the Caliper Luminal IVIS Ⅱ small animal imaging system at different time after injection. Results Near-infrared images were acquired at 1, 2, 15, 24, and 48 hours post-injection by using in vivo NIR imaging. For the experimental group, the fluorescence intensity of the tumor in the right hind limb was(5.82 ± 1.24) × 10^7 photons/(s·cm2),(8.99 ± 1.27) × 10^7photons/(s·cm2),(4.04 ± 2.30) × 10^7 photons/(s·cm2),(6.52 ± 3.93) × 10^7 photons/(s·cm2),(9.33 ± 1.74) × 107photons/(s·cm^2), which were higher than those in the left hind limb, respectively. The results of the experimental group in the right hind limb was(18.4 ± 1.33) × 10^7 photons/(s·cm^2),(17.1 ± 1.64) × 10^7 photons/(s·cm^2),(55.8 ± 2.66) × 107photons/(s·cm^2),(68.9 ± 3.97) × 10^7 photons/(s·cm^2),(16.3 ± 1.67) × 10^7 photons/(s·cm^2), which were higher than those in the control group, respectively. There was still high fluorescence distribution in the liver and kidney at 48 hours postinjection. Conclusion HVGGSSV peptide could specifically bind to irradiated hepatic tumors, and mainly metabolized in the kidney and liver, it might provide a targeting transport agent for radiation-guided drugs.
出处 《中国肝脏病杂志(电子版)》 CAS 2015年第4期54-58,共5页 Chinese Journal of Liver Diseases:Electronic Version
基金 福建省自然科学基金(No.2012J01331)
关键词 多肽HVGGSSV 顺铂(DDP) 放射引导的药物传输 肝癌移植瘤模型 HVGGSSV DDP Radiation-guided drug delivery Hepatocarcinoma Xenograft model
  • 相关文献

参考文献17

  • 1McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation[J]. Proc Natl Acad Sci U S A,2006,103:1041- 1046.
  • 2Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions[J]. Drug Discov Today,2015,20:122-128.
  • 3Mathews AS, Ahmed S, Shahin M, et al. Peptide modified polymeric micelles specific for breast cancer cells[J]. Bioconjug Chem,2013,24:560-570.
  • 4D'Onofrio N, Caraglia M, Grimaldi A, et al. Vascular-homing peptides for targeted drug delivery and molecular imaging: meeting the clinical challenges[J]. Biochim Biophys Acta,2014,1846:1-12.
  • 5de Figueiredo IR, Freire JM, Flores L, et al. Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies[J]. IUBMB life,2014,doi: 10.1002/iub.1257.
  • 6Lowery A, Onishko H, Hallahan DE, et al. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors[J]. J Control Release,2011,150:117-124.
  • 7Passarella RJ, Zhou L, Phillips JG, et al. Recombinant peptides as biomarkers for tumor response to molecular targeted therapy[J]. Clin Cancer Res,2009,15:6421-6429.
  • 8Wang H, Yan H, Fu A, et al. TIP-I translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation[J]. PLoS One,2010,5:e 12051.
  • 9Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action[J]. Eur J Pharrnacol,2014,740:364-378.
  • 10Toulany M, Mihatsch J, Holler M, et al. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition[J]. Radiother Oncol,2014,111:228-236.

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部